A recent study suggests that people who discontinue new slimming jabs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who end traditional diet and exercise regimens.
Published data in a prominent medical journal points out that while overweight people often shed a large proportion of their total mass while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Users buying these medications should be informed of the danger of rapid rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.
That rate of recovery means a reversion to starting mass in about a year and a half.
Weighing Approaches
The research, which reviewed dozens of studies involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.
Researchers emphasize that individuals who lose weight through lifestyle changes alone generally experience a slower creep back—perhaps 100 grams monthly—post-intervention.
The Reason for the Rapid Regain
Experts suggest the way of the injections is key to understanding the amplified rebound.
These medications mimic a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal might result in the body to produce less of its own natural GLP-1, and could lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating much more probable."
A Chronic Disease?
The NHS advise the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals contend that, considering the high risk of weight regain, the treatment should be considered long-term.
This view is echoed by drug manufacturers, who state that the results "emphasize the chronic nature of excess weight," comparing it to managing conditions like diabetes.
Patient Accounts
People who have discontinued the medication describe a sudden return of cravings.
"I experienced something activating and you become ravenous," recalled an individual.
The struggle is compounded if individuals have not established lasting lifestyle or habit modifications during treatment.
Growing Interest
Figures suggest that millions of adults in the UK have tried these injections in the past year, with desire remaining high.
- Adoption is greater among women compared to males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent solution and maintained weight loss likely depends on integrated lifestyle changes.
